AR and prostate adenocarcinoma: In contrast, neuroendocrine prostate cancer (NEPC) is a highly aggressive form of PCa, that rarely arises de novo and most often emerges from prostate adenocarcinoma after androgen deprivation or androgen receptor (AR) targeted therapy [10].